Moreover, proximal tumors were more frequently MSI, hypermutated, BRAF mutant, and densely infiltrated by TIL, whereas distal tumors were CIN, HER1, and HER2 amplified, with active EGFR signaling and mostly non-BRAF-like characteristics according to an analysis of molecular features along anatomical sites in colon carcinomas of patients enrolled in the Pan European Trial Adjuvant Colon Cancer-3 (PETACC3) chemotherapy trial (52), indicating a great heterogeneity within CRC. This evidence concerns the gene EGFR and malignant colon neoplasm.